<DOC>
	<DOCNO>NCT00002939</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness irinotecan paclitaxel treat patient metastatic recurrent cancer .</brief_summary>
	<brief_title>Irinotecan Paclitaxel Treating Patients With Metastatic Recurrent Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) irinotecan administer combination paclitaxel patient metastatic recurrent malignancy . II . Evaluate toxicity safety combination regimen patient population . III . Determine pharmacokinetic profile irinotecan combination paclitaxel weekly schedule sequence administration influence irinotecan pharmacokinetics patient . IV . Determine pharmacodynamic model irinotecan SN-38 SN-38G metabolite administer weekly combination schedule . OUTLINE : This dose escalation study irinotecan . Patients receive irinotecan IV concurrently paclitaxel IV weekly . Patients demonstrate stable disease partial complete clinical response continue treatment long dose limit toxicity observe adequate performance status maintain . Cohorts 3 patient receive escalate dos irinotecan maximum tolerate dose determine 150 mg/m2 reach . PROJECTED ACCRUAL : A total 36 patient accrue study .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm non hematologic malignancy refractory standard therapy , know effective therapy exist PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : At least 3 month Hematopoietic : Platelet count least 100,000/mm3 Absolute neutrophil count least 2,000/mm3 Absolute lymphocyte count least 1,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Transaminase great 2.5 time upper limit normal Renal : Creatinine great 1.4 mg/dL Cardiovascular : No myocardial infarction within 6 month No current , uncontrolled cardiac arrhythmia Other : No history anaphylactic reaction Not pregnant Fertile patient must use effective contraception No serious uncontrolled , concurrent medical disorder PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior paclitaxel allow No prior irinotecan At least 4 week since prior chemotherapy Endocrine therapy : No concurrent steroids Radiotherapy : At least 4 week since prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>